其他安全警示

Canada: Health Canada updates Canadians on its ongoing assessment of nitrosamine impurities in certain drugs (English only)

Health Canada announces that it has been working to address the issue of N-nitrosodimethylamine (NDMA) and similar nitrosamine impurities found in certain “sartan” angiotensin receptor blocker (ARB) blood pressure medications since 2018 and, certain ranitidine drugs more recently.

Health Canada has expanded its efforts to evaluate the potential for nitrosamines in drugs other than sartans and ranitidine, along with measures to address and prevent the impurities. Health Canada has also shared information with all Canadian drug companies on the root causes of the impurities that have been identified to date. It has requested that companies:
- review their products and manufacturing processes for the possible presence of nitrosamines;
- take any necessary measures to ensure that their products do not contain nitrosamines at levels exceeding the accepted limit;
- test products if a risk of nitrosamines is identified; and
- immediately report to Health Canada if nitrosamines are detected.

In addition to testing by companies, the Department has conducted its own testing of certain sartan and ranitidine drugs, and has developed laboratory test methods to provide validated testing options for use by industry and other regulators.

The Department has also been working in collaboration with its international partners, including the US Food and Drug Administration (FDA) and the European Medicines Agency. Health Canada is aware that US FDA testing has detected NDMA in nizatidine, a prescription drug that is chemically similar to ranitidine. Nizatidine is sold in Canada only under the brand name Axid. In light of this information, and at Health Canada’s request, the company (Pendopharm Division of Pharmascience Inc.) has voluntarily stopped sale of this drug in Canada while it investigates the issue. Axid is not being recalled in Canada at this time.

Health Canada continues to work with companies and international partners to understand the root causes of nitrosamines in drugs. The Department will take action if a risk to Canadians is identified, and will be vigilant in informing the public of any new safety information.

Please refer to the following website in Health Canada for details: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../71770a-eng.php

In Hong Kong, there is no registered pharmaceutical product containing nizatidine.

Ends/ Tuesday, Dec 3, 2019
Issued at HKT 17:00

Related Information:

Canada: Pharmascience Inc. recalls 30 lots of 150 mg over-the-counter ranitidine... 上载于 2022-03-12

Canada: Ranitidine products recalled because of a nitrosamine impurity (English ... 上载于 2021-12-04

Canada: Pharmascience Inc. recalls certain lots of prescription and over-the-cou... 上载于 2021-02-06

Canada: Pharmascience Inc. recalls additional lots of over-the-counter ranitidin... 上载于 2021-02-01

Canada: Pharmascience Inc. recalls certain lots of over-the-counter ranitidine (... 上载于 2021-01-11

Canada: Pharmascience Inc. recalls one lot of PMS-Ranitidine as a precaution (En... 上载于 2020-09-01

台湾：回收悦拟停膜衣锭150毫克 Ranitidine F.C. Tablets 150mg "CYH" 上载于 2020-08-19

台湾：回收胃治溃膜衣锭300公丝（盐酸雷尼得定）VESYCA FILM COATED TABLETS 300MG (RANITIDINE HYDROCHLORI... 上载于 2020-08-19

台湾：回收胃治溃注射液25公丝/公撮（雷尼得定）VESYCA INJECTION 25MG/ML (RANITIDINE) 上载于 2020-08-19

台湾：回收溃特得膜衣锭150公丝（盐酸雷尼得定）ULSAFE F.C. TABLETS 150MG (RANITIDINE HYDROCHLORIDE) 上载于 2020-08-19

台湾：回收固胃治溃膜衣锭GASWELL FILM COATED TABLETS 上载于 2020-08-19